InsidersTradesSigma
PHARMANUTRA PHARMANUTRA - PHN: IL CDA APPROVA IL PROGETTO DI BILANCIO DI ESERCIZIO E IL BILANCIO CONSOLIDATO AL 31 DICEMBRE 2025 Stock: price and management transactions · Italy · Consob
CONSOB:pharmanutra-pharmanutra-phn-il-cda-approva-il-progetto-di-bilancio-di-esercizio-IT·ConsobMcap €889.5MHealth Care
Follow the PHARMANUTRA PHARMANUTRA - PHN: IL CDA APPROVA IL PROGETTO DI BILANCIO DI ESERCIZIO E IL BILANCIO CONSOLIDATO AL 31 DICEMBRE 2025 stock price and the full management transaction log of the company, a listed equity based in Italy. Shares trade on IT IT, under the supervision of Consob. Operating in the Health Care sector, PHARMANUTRA PHARMANUTRA - PHN: IL CDA APPROVA IL PROGETTO DI BILANCIO DI ESERCIZIO E IL BILANCIO CONSOLIDATO AL 31 DICEMBRE 2025 has published 1 public disclosures. Market capitalisation: €889.5m. The latest transaction was filed on 17 March 2026 (Other). Among the most active insiders: Unknown. The full history is openly available.
1
Insider Decl.
0
Thresholds
·
0 ops.
Buy Volume
·
0 ops.
Sell Volume
Fundamental score
Ranked 7,850 of 26,212 companies
61.4
score / 100
Value38
Quality85
FCF yld1.9%
Earn yld2.3%
EV/EBITDA25.6x
ROE30%
Gross mgn77%
Net mgn15%
Debt/EBITDA0.6x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 17 March 2026